United States securities and exchange commission logo

                 April 14, 2022

       Eric A. Adams
       Chief Executive Officer
       InMed Pharmaceuticals Inc.
       Suite 310     815 West Hastings Street
       Vancouver, British Columbia V6C 1B4

                                                        Re: InMed
Pharmaceuticals Inc.
Statement on Form S-3
                                                            Filed April 7, 2022
                                                            File No. 333-264187

       Dear Mr. Adams:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

             Please contact Michael Davis at 202-551-4385 or Christine
Westbrook at 202-551-
       5019 with any questions.


                 Division of Corporation Finance

                 Office of Life Sciences
       cc:                                              Brian P. Fenske, Esq.